Sino Biopharmaceutical (HK:1177) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Sino Biopharmaceutical has announced positive results from its Phase III study of Benmelstobart Injection combined with chemotherapy, followed by Anlotinib Hydrochloride Capsules as a first-line treatment for advanced squamous non-small cell lung cancer. The interim analysis showed significant improvement in progression-free survival compared to the existing treatment, marking a promising development for patients with this challenging cancer subtype. The company plans to submit a marketing application for this new indication soon, which could offer new hope for cancer treatment.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
